Third-generation anti-CD19 CAR T-cells show efficacy without neurotoxicity in B-cell lymphoma phase 1 clinical trial
The Malaghan Institute of Medical Research, in collaboration with Wellington Zhaotai Therapies Limited, today announced results of its phase 1 dose escalation trial of a new third generation anti-CD19 chimeric antigen receptor ...
Dec 11, 2023
0
0